BioCentury
ARTICLE | Clinical News

Human neural stem cells: Phase I start

January 21, 2013 8:00 AM UTC

This quarter, Neuralstem will begin an open-label, U.S. Phase I trial to evaluate 6 injections of NSI-566 in or around the injury site 1-2 years after injury in up to 8 patients with thoracic SCI classified as American Spinal Injury Association Impairment Scale (AIS) level A. AIS A is considered to be complete paralysis. The first 4 patients will receive injections of 100,000 cells, and the second 4 patients will receive injections of 200,000 cells. Patients will also receive physical therapy after surgery and immunosuppressive therapy. ...